Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > BUSINESS
BUSINESS
- Takecab Most Heavily Pitched Drug in HP Market in January: Anterio
March 9, 2017
- Yutaka Shibata to Helm Asahi Kasei Pharma
March 9, 2017
- Pfizer’s FY2016 Japan Sales Slide 7.4% on Price Cuts, Generic Erosions
March 9, 2017
- Fujifilm Succeeds at Increasing Anti-Inflammatory Action of Mesenchymal Stem Cells, Expects Uses in Regenerative Medicine
March 9, 2017
- Average Drug R&D Spending in Japan Up 1.46 Billion Yen in FY2015
March 8, 2017
- Ethical Drug Sales Down 6.8% in January: Crecon
March 8, 2017
- Avelumab Filed in Japan for Merkel Cell Carcinoma: Merck Serono/Pfizer
March 8, 2017
- Taiho Forms Canadian Unit for Lonsurf Rollout
March 8, 2017
- Edoxaban Study in Post-PCI AF Patients Underway: Daiichi Sankyo
March 8, 2017
- Fujifilm, Kyowa Kirin JV Wins Humira Patent Litigation in UK
March 7, 2017
- Mochida, Fuji Yakuhin Link Arms on Hyperuricemia Candidate
March 7, 2017
- Maruho Group to See 1st Overseas Launch Next Month with Acne Med
March 7, 2017
- Kanako Kikuchi to Become Japan Chief of GSK
March 7, 2017
- Otsuka to Buy Neurovance, Gets Its Hands on Non-Stimulant ADHD Med
March 6, 2017
- Bioverativ Japan Now Up and Running, Set to Keep Double-Digit Growth: President
March 3, 2017
- NCC, Daiichi Sankyo Begin PI on Mutant IDH1 Inhibitor for Glioma
March 2, 2017
- Fujifilm Creates Bio CDMO Division, Aims for 100 Billion Yen Sales in FY2023
March 2, 2017
- GSK Remains Strong Player in Respiratory, Japan Sales Slip 1.7%: Fauchet
March 1, 2017
- Nobelpharma Forms Preparatory Office for Overseas Biz
March 1, 2017
- ASKA Gets Asian Rights to Pieris’ Anemia Med
March 1, 2017
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…